| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Yu Du, Ren-Jie Xia, Li-Wen Shen, Jian-Guo Ma, Wei-Qing Yao, Wei Xu, Zhi-Peng Lin, Liang-Bin Ma, Guo-Qiang Niu, Rui-Fang Fan, Shu-Mei Xu and Long Yan |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Health Industry Research Program of Gansu Province |
GSWSKY2021-043 |
| the Youth Science and Technology Foundation of Gansu Province |
22JR11RA002 |
| the Natural Science Foundation of Gansu Province |
22JR5RA008 |
|
| Corresponding Author |
Long Yan, Associate Chief Physician, MD, Departmen of Hepatobiliary Surgery and General Surgery, The 940th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, No. 333 Nanbinhe Middle Road, Qilihe District, Lanzhou 730050, Gansu, China. lzzy940@163.com |
| Key Words |
Unresectable locally advanced gastric adenocarcinoma; Conversion therapy; Immunotherapy; Programmed cell death protein 1 inhibitors; Sintilimab |
| Core Tip |
The prognosis for patients with unresectable or metastatic gastric cancer remains poor. The efficacy and safety of chemotherapy and immunotherapy require further improvement. We have designed an innovative first-line quadruple conversion therapy regimen that integrates a programmed cell death protein 1 inhibitor with chemotherapy, successfully implemented in the treatment of a patient with unresectable locally advanced gastric adenocarcinoma. |
| Publish Date |
2025-03-25 16:19 |
| Citation |
<p>Du XY, Xia RJ, Shen LW, Ma JG, Yao WQ, Xu W, Lin ZP, Ma LB, Niu GQ, Fan RF, Xu SM, Yan L. Quadruple therapy with immunotherapy and chemotherapy as first-line conversion treatment for unresectable advanced gastric adenocarcinoma: A case report. <i>World J Gastrointest Oncol</i> 2025; 17(4): 102258</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/102258.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.102258 |
